Your browser is no longer supported. Please, upgrade your browser.
CAPR Capricor Therapeutics, Inc. monthly Stock Chart
CAPR [NASD]
Capricor Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own0.50% Shs Outstand20.45M Perf Week-2.33%
Market Cap80.68M Forward P/E- EPS next Y-1.01 Insider Trans0.00% Shs Float19.93M Perf Month0.96%
Income-10.90M PEG- EPS next Q-0.20 Inst Own6.40% Short Float6.23% Perf Quarter-30.35%
Sales0.50M P/S161.36 EPS this Y60.10% Inst Trans43.89% Short Ratio1.58 Perf Half Y-12.68%
Book/sh1.54 P/B2.73 EPS next Y-14.80% ROA-44.40% Target Price- Perf Year170.97%
Cash/sh1.84 P/C2.29 EPS next 5Y- ROE-55.80% 52W Range0.88 - 12.32 Perf YTD228.12%
Dividend- P/FCF- EPS past 5Y17.30% ROI-75.80% 52W High-65.91% Beta6.66
Dividend %- Quick Ratio15.60 Sales past 5Y-26.80% Gross Margin- 52W Low377.27% ATR0.30
Employees16 Current Ratio15.60 Sales Q/Q-88.10% Oper. Margin- RSI (14)45.11 Volatility7.34% 7.26%
OptionableYes Debt/Eq0.12 EPS Q/Q53.90% Profit Margin- Rel Volume0.61 Prev Close4.29
ShortableYes LT Debt/Eq0.12 EarningsNov 12 AMC Payout- Avg Volume785.53K Price4.20
Recom2.00 SMA20-0.50% SMA50-8.88% SMA200-3.49% Volume478,760 Change-2.10%
Dec-26-18Downgrade Maxim Group Buy → Hold
Jan-26-18Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17Resumed Rodman & Renshaw Buy $14
Jul-06-16Resumed H.C. Wainwright Buy $13
Jun-15-16Initiated ROTH Capital Buy
Nov-24-20 07:30AM  
Nov-12-20 04:01PM  
02:30PM  
Nov-09-20 09:15AM  
Nov-05-20 09:00AM  
Sep-23-20 09:25AM  
Sep-10-20 09:15AM  
Sep-01-20 04:34PM  
Aug-31-20 09:00AM  
Aug-25-20 11:34AM  
09:15AM  
Aug-06-20 04:01PM  
Jul-30-20 09:15AM  
Jul-28-20 12:33PM  
Jul-23-20 07:28AM  
Jun-04-20 09:15AM  
May-29-20 01:08PM  
May-26-20 09:25AM  
May-14-20 05:35PM  
04:01PM  
May-13-20 04:30PM  
07:00AM  
May-06-20 06:44PM  
Apr-30-20 12:23AM  
Apr-29-20 09:15AM  
Apr-24-20 07:31AM  
Apr-13-20 09:00AM  
Apr-06-20 04:02PM  
Apr-03-20 08:00AM  
Mar-24-20 08:00AM  
Mar-19-20 08:30AM  
Mar-18-20 04:01PM  
02:30PM  
Mar-17-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 07:01AM  
Feb-13-20 11:30AM  
Feb-07-20 04:12PM  
Feb-03-20 07:39AM  
Jan-28-20 07:01AM  
Dec-19-19 01:14PM  
Dec-17-19 01:52PM  
Dec-11-19 05:29AM  
Nov-07-19 05:15PM  
04:00PM  
Nov-01-19 09:00AM  
Oct-27-19 09:16AM  
Oct-21-19 09:25AM  
Oct-14-19 09:35AM  
Oct-07-19 12:27PM  
06:30AM  
Oct-04-19 10:09AM  
Oct-02-19 09:15AM  
Oct-01-19 09:14AM  
Sep-26-19 11:24AM  
09:47AM  
Sep-25-19 08:44AM  
Sep-24-19 11:25AM  
09:20AM  
07:42AM  
07:30AM  
Sep-23-19 09:44AM  
Sep-21-19 08:20AM  
Sep-20-19 09:12AM  
Sep-19-19 08:41AM  
Sep-17-19 12:29PM  
08:38AM  
07:00AM  
Sep-11-19 09:04AM  
Sep-06-19 07:30AM  
Aug-23-19 08:37AM  
Aug-22-19 07:31AM  
Aug-20-19 09:03AM  
Aug-16-19 10:24AM  
Aug-06-19 06:05PM  
04:00PM  
Aug-01-19 10:32AM  
Jul-30-19 08:00AM  
Jul-25-19 07:00AM  
Jul-17-19 07:00AM  
Jul-16-19 12:44PM  
Jul-15-19 02:59PM  
08:45AM  
06:00AM  
Jul-02-19 02:23PM  
May-13-19 05:15PM  
04:06PM  
04:00PM  
02:30PM  
May-06-19 04:00PM  
Apr-05-19 10:52AM  
Mar-28-19 04:25PM  
04:00PM  
Mar-21-19 08:00AM  
Feb-21-19 07:40AM  
Feb-06-19 07:00AM  
Jan-24-19 09:30AM  
07:00AM  
Jan-22-19 07:00AM  
Jan-18-19 02:56PM  
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manzo LouisDirectorSep 24Option Exercise3.708,29930,70644,603Sep 28 08:30 AM
Marban LindaCHIEF EXECUTIVE OFFICERJul 27Option Exercise3.7041,497153,53962,367Jul 29 06:39 PM